CA2780137C - Phototriggered nanoparticles for cell and tissue targeting - Google Patents

Phototriggered nanoparticles for cell and tissue targeting Download PDF

Info

Publication number
CA2780137C
CA2780137C CA2780137A CA2780137A CA2780137C CA 2780137 C CA2780137 C CA 2780137C CA 2780137 A CA2780137 A CA 2780137A CA 2780137 A CA2780137 A CA 2780137A CA 2780137 C CA2780137 C CA 2780137C
Authority
CA
Canada
Prior art keywords
ligand
composition
protecting group
particles
photo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2780137A
Other languages
English (en)
French (fr)
Other versions
CA2780137A1 (en
Inventor
Tal Dvir
Daniel S. Kohane
Matthew Ryan Banghart
Robert S. Langer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Massachusetts Institute of Technology
Harvard University
Original Assignee
Boston Childrens Hospital
Massachusetts Institute of Technology
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital, Massachusetts Institute of Technology, Harvard University filed Critical Boston Childrens Hospital
Publication of CA2780137A1 publication Critical patent/CA2780137A1/en
Application granted granted Critical
Publication of CA2780137C publication Critical patent/CA2780137C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
CA2780137A 2009-09-30 2010-09-30 Phototriggered nanoparticles for cell and tissue targeting Expired - Fee Related CA2780137C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24753509P 2009-09-30 2009-09-30
US61/247,535 2009-09-30
PCT/US2010/050846 WO2011041496A1 (en) 2009-09-30 2010-09-30 Phototriggered nanoparticles for cell and tissue targeting

Publications (2)

Publication Number Publication Date
CA2780137A1 CA2780137A1 (en) 2011-04-07
CA2780137C true CA2780137C (en) 2014-07-22

Family

ID=43826645

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2780137A Expired - Fee Related CA2780137C (en) 2009-09-30 2010-09-30 Phototriggered nanoparticles for cell and tissue targeting

Country Status (12)

Country Link
US (1) US20130004522A1 (https=)
EP (1) EP2482922A1 (https=)
KR (1) KR20120080615A (https=)
CN (1) CN102883773A (https=)
AU (1) AU2010300629A1 (https=)
BR (1) BR112012009182A2 (https=)
CA (1) CA2780137C (https=)
IL (1) IL218964A0 (https=)
IN (1) IN2012DN03178A (https=)
MX (1) MX2012003990A (https=)
RU (1) RU2012117418A (https=)
WO (1) WO2011041496A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE509692T1 (de) 2003-07-17 2011-06-15 Unilever Nv Verfahren zur herstellung einer öl und strukturierungsmittel enthaltenden essbaren dispersion
WO2006087090A1 (en) 2005-02-17 2006-08-24 Unilever N.V. Granules comprising sterol
WO2010033200A2 (en) 2008-09-19 2010-03-25 President And Fellows Of Harvard College Creation of libraries of droplets and related species
AU2009328392B2 (en) 2008-12-19 2013-08-22 Upfield Europe B.V. Edible fat powders
EA024216B1 (ru) 2010-06-22 2016-08-31 Юнилевер Н.В. Порошкообразные пищевые жиры
MX337914B (es) 2010-12-17 2016-03-28 Unilever Nv Proceso para compactar polvo de grasa microporosa y polvo de grasa compactado asi obtenido.
MX342040B (es) 2010-12-17 2016-09-12 Unilever Nv Emulsion de agua en aceite comestible.
WO2015069634A1 (en) * 2013-11-08 2015-05-14 President And Fellows Of Harvard College Microparticles, methods for their preparation and use
CN103623417B (zh) * 2013-12-18 2016-01-20 东华大学 一种功能化聚酰胺-胺树状大分子的纳米复合物的应用
JP2018537414A (ja) 2015-10-13 2018-12-20 プレジデント アンド フェローズ オブ ハーバード カレッジ ゲルマイクロスフェアの作製及び使用のためのシステム及び方法
JP7297065B2 (ja) * 2019-07-01 2023-06-23 富士フイルム株式会社 イメージセンサ
KR20210149956A (ko) * 2020-06-02 2021-12-10 삼성디스플레이 주식회사 양자점 조성물, 발광 소자 및 이의 제조 방법
CN114574187B (zh) * 2020-11-30 2024-03-05 北京京东方技术开发有限公司 纳米粒子、纳米粒子层图案化的方法及相关应用
WO2022134039A1 (zh) * 2020-12-25 2022-06-30 京东方科技集团股份有限公司 量子点材料、发光器件及其制作方法、显示装置
CN115244702B (zh) * 2021-02-23 2025-03-11 京东方科技集团股份有限公司 量子点发光器件及其制作方法、显示装置
US12187935B1 (en) * 2023-12-12 2025-01-07 Applied Materials, Inc. Liquid dispersion of quantum dots in an acrylic monomer medium

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998580A (en) * 1995-10-13 1999-12-07 Fay; Frederick F. Photosensitive caged macromolecules
US20070041934A1 (en) * 2005-08-12 2007-02-22 Regents Of The University Of Michigan Dendrimer based compositions and methods of using the same
WO2008109161A2 (en) * 2007-03-07 2008-09-12 The Albert Einstein College Of Medicine Of Yeshiva University Deeply quenched enzyme sensors

Also Published As

Publication number Publication date
IL218964A0 (en) 2012-06-28
MX2012003990A (es) 2012-06-27
KR20120080615A (ko) 2012-07-17
EP2482922A1 (en) 2012-08-08
AU2010300629A1 (en) 2012-06-21
WO2011041496A1 (en) 2011-04-07
IN2012DN03178A (https=) 2015-09-25
CA2780137A1 (en) 2011-04-07
US20130004522A1 (en) 2013-01-03
RU2012117418A (ru) 2013-11-10
CN102883773A (zh) 2013-01-16
BR112012009182A2 (en) 2018-03-20

Similar Documents

Publication Publication Date Title
CA2780137C (en) Phototriggered nanoparticles for cell and tissue targeting
TWI741064B (zh) 用於修飾介導生物活性或與生物活性有關之靶結構之醫藥組合物及套組
Li et al. Near-infrared light-triggered release of small molecules for controlled differentiation and long-term tracking of stem cells in vivo using upconversion nanoparticles
Xu et al. Near-infrared-triggered photodynamic therapy with multitasking upconversion nanoparticles in combination with checkpoint blockade for immunotherapy of colorectal cancer
Mitragotri et al. Accelerating the translation of nanomaterials in biomedicine
Cho et al. Engineered photo-responsive materials for near-infrared-triggered drug delivery
Nakki et al. Chlorin e6 functionalized theranostic multistage nanovectors transported by stem cells for effective photodynamic therapy
TW200946164A (en) Methods and systems for treating cell proliferation disorders using plasmonics enhanced photospectral therapy (PEPST) and exciton-plasmon enhanced phototherapy (EPEP)
Li et al. Cancer cell membrane biomimetic nanosystem for homologous targeted dual-mode imaging and combined therapy
Shah The nanomaterial toolkit for neuroengineering
Tang-Schomer et al. Film interface for drug testing for delivery to cells in culture and in the brain
Chen et al. Advancing oral cancer care: nanomaterial-driven diagnostic and therapeutic innovations
You et al. Adaptive dual-responsive nanocapsules for precision ferroptosis-driven and chemotherapy-enhanced tumor ablation
US20080260725A1 (en) Tag and target delivery system
KR20160013474A (ko) 광감작제 담지 탄산칼슘 복합 나노입자, 이의 제조방법 및 이를 포함하는 초음파 조영 및 광역학 치료용 조성물
US10183081B2 (en) Use of scintillator-based nanoparticles for in vivo control of light-sensitive bioactive molecules
Nazarnezhad et al. Cancer diagnosis and therapy by electrospun nanofibers: Opportunities and challenges
Jiang Nanobubble-assisted ultrasound theragnostics in cellular immunotherapy for cancers
Gorgania et al. in cancer precision medicine
Dahman et al. Nanotechnology and its Applications in Biomedical Engineering
Zhang et al. In Vivo Programmed Assembly of Polymer–Peptide Conjugates to Overcome Multistage Drug Delivery Barriers
Boto Leukemia Cells Modulation by Light-Activatable Nanoparticles
He et al. Engineering glioma cell-derived exosome as Trojan horse for precisely targeted chemotherapy of glioblastoma​

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150930